» » »

Melanoma Vaccine Boone NC

A vaccine for advanced melanoma has shown promise in a new study. Melanoma is the most serious type of skin cancer in Boone. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

Appalachian - New River Veterinary Associates
(828) 264-5621
218 Wilson Dr
Boone, NC

Data Provided by:
Robert C Snyder
(828) 268-0064
237 Longvue Dr
Boone, NC
Specialty
Internal Medicine

Data Provided by:
LeVerne S Fox
(828) 264-9664
175 Mary St
Boone, NC
Specialty
Cardiology, Internal Medicine, Cardiovascular Disease

Data Provided by:
Marye Elizabeth Hacker
(828) 262-4399
336 Deerfield Rd
Boone, NC
Specialty
Family Practice, Emergency Medicine

Data Provided by:
Robert Finch Griffith
(828) 262-0060
136 Furman Rd
Boone, NC
Specialty
Internal Medicine

Data Provided by:
Thomas J Zuber
(828) 262-1800
245 Winklers Creek Rd
Boone, NC
Specialty
Family Practice, Geriatric Medicine

Data Provided by:
Juan Carlos De Virgiliis
(828) 262-3733
381 Deerfield Rd
Boone, NC
Specialty
Family Practice

Data Provided by:
Bill J Beason
(828) 264-4533
237 Longvue Dr
Boone, NC
Specialty
Family Practice

Data Provided by:
Forrest Matt Brown
(828) 264-6362
108 Doctors Dr
Boone, NC
Specialty
Internal Medicine

Data Provided by:
Terry Joseph McAnallen
(828) 264-7311
240 Highway 105 Ext Ste 100
Boone, NC
Specialty
Family Practice

Data Provided by:
Data Provided by:

Melanoma Vaccine

Provided By:

SATURDAY, May 30 (HealthDay News) --A vaccine for advanced melanoma has shown promise in a new study.

Melanoma is the most serious type of skin cancer. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

The study, a phase 3 clinical trial involving 185 people, found that using the peptide vaccine in combination with the immunotherapy drug Interleukin-2 improved response rates and progression-free survival, according to University of Texas M.D. Anderson Cancer Center researchers, who said it was the first phase 3 trial to show a clinical benefit in a vaccine for melanoma.

Response rate and progression-free survival were 22.1 percent and 2.9 months, respectively, in people given the vaccine, compared with 9.7 percent and 1.6 months for those who were not vaccinated. Median overall survival was 17.6 months for the vaccine group and 12.8 months for the others.

The study, which was to be presented Saturday at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla., was funded in part by Novartis, which makes Interleukin-2.

"Obviously this is a disease, in its advanced setting, in need of better therapies for our patients," study co-author Dr. Patrick Hwu, a professor and chairman of M.D. Anderson's Department of Melanoma Medical Oncology, said in a news release from the center.

"While more follow-up is needed, this study serves as a proof-of-principle for vaccines' role in melanoma and in cancer therapy overall," Hwu said. "If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue."

The vaccine, called gp100:209-217 (200M), works by stimulating T-cells, which control immune response.

"This vaccine activates the body's cytotoxic T-cells to recognize antigens on the surface of the tumor," Hwu said. "The T-cells then secrete enzymes that poke holes in the tumor cell's membrane, causing it to disintegrate."

More information

The Skin Cancer Foundation has more about melanoma.

SOURCE: University of Texas M.D. Anderson Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com